Pharmacokinetics of fixed-dose combination of tenofovir disoproxil fumarate, lamivudine, and efavirenz: results of a randomized, crossover, bioequivalence study.

about

Pharmacokinetics of fixed-dose combination of tenofovir disoproxil fumarate, lamivudine, and efavirenz: results of a randomized, crossover, bioequivalence study.

Item

http://www.wikidata.org/entity/Q39673548

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Pharmacokinetics of fixed-dose ...... ossover, bioequivalence study.

@en

Pharmacokinetics of fixed-dose ...... ossover, bioequivalence study.

@nl

type

Item

label

Pharmacokinetics of fixed-dose ...... ossover, bioequivalence study.

@en

Pharmacokinetics of fixed-dose ...... ossover, bioequivalence study.

@nl

prefLabel

Pharmacokinetics of fixed-dose ...... ossover, bioequivalence study.

@en

Pharmacokinetics of fixed-dose ...... ossover, bioequivalence study.

@nl

P1476

Pharmacokinetics of fixed-dose ...... ossover, bioequivalence study.

@en

P2093

Ashish Shedage

http://www.w3.org/2001/XMLSchema#string

Dhiraj Abhyankar

http://www.w3.org/2001/XMLSchema#string

Milind Gole

http://www.w3.org/2001/XMLSchema#string

Preeti Raut

http://www.w3.org/2001/XMLSchema#string

P2860

Combinatorial approaches to the prevention and treatment of HIV-1 infection

Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy.

Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults.

Better physician-patient relationships are associated with higher reported adherence to antiretroviral therapy in patients with HIV infection

Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily.

Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring

Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons.

HIV/AIDS patients display lower relative bioavailability of efavirenz than healthy subjects.

HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy.

Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions.

P304

491-498

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0956462416655955

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27317878

http://www.w3.org/2001/XMLSchema#string